Novel approaches to the treatment of acute myeloid leukemia.

Abstract

Approximately 12 000 adults are diagnosed with acute myeloid leukemia (AML) in the United States annually, the majority of whom die from their disease. The mainstay of initial treatment, cytosine arabinoside (ara-C) combined with an anthracycline, was developed nearly 40 years ago and remains the worldwide standard of care. Advances in genomics technologies have identified AML as a genetically heterogeneous disease, and many patients can now be categorized into clinicopathologic subgroups on the basis of their underlying molecular genetic defects. It is hoped that enhanced specificity of diagnostic classification will result in more effective application of targeted agents and the ability to create individualized treatment strategies. This review describes the current treatment standards for induction, consolidation, and stem cell transplantation; special considerations in the management of older AML patients; novel agents; emerging data on the detection and management of minimal residual disease (MRD); and strategies to improve the design and implementation of AML clinical trials.

• Authors: Gail J Roboz
• Journal: Hematology. American Society of Hematology. Education Program (Hematology Am Soc Hematol Educ Program) Vol. 2011 Pg. 43-50 ( 2011) ISSN: 1520-4383 [Electronic] United States
• PMID: 22160011 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (therapeutic use)
• Hematology (methods)
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myeloid, Acute (drug therapy, therapy)
• Molecular Targeted Therapy
• Neoplasm, Residual (drug therapy)